Infections and immune dysregulation in ataxia-telangiectasia children with hyper-IgM and non-hyper-IgM phenotypes: A single-center experience.
ataxia-telangiectasia
immune dysregulation
inborn errors of immunity
infection
malignancy
syndromic immunodeficiency
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
06
2022
accepted:
28
09
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
8
11
2022
Statut:
epublish
Résumé
Ataxia-telangiectasia (A-T) is a severe syndromic neurodegenerative inborn error of immunity characterized by DNA reparation defect, chromosomal instability, and hypersensitivity to ionizing radiation, thereby predisposing affected individuals to malignant transformation. While the leading disease symptomatology is associated with progressively debilitating cerebellar ataxia accompanied by central and peripheral nervous system dysfunctions, A-T is a multisystemic disorder manifesting with the heterogeneity of phenotypic features. These include airway and interstitial lung disease, chronic liver disease, endocrine abnormalities, and cutaneous and deep-organ granulomatosis. The impaired thymic T cell production, defective B cell development and antibody production, as well as bone marrow failure, contribute to a combined immunodeficiency predisposing to infectious complications, immune dysregulation, and organ-specific immunopathology, with the A-T hyper-IgM (HIGM) phenotype determining the more severe disease course. This study aimed to clarify the immunodeficiency and associated immune dysregulation as well as organ-specific immunopathology in children with A-T. We also sought to determine whether the hyper-IgM and non-hyper-IgM phenotypes play a discriminatory role and have prognostic significance in anticipating the clinical course and outcome of the disease. We retrospectively reviewed the medical records of twelve A-T patients, aged from two to eighteen years. The patients' infectious history, organ-specific symptomatology, and immunological workup including serum alpha-fetoprotein, immunoglobulin isotypes, IgG subclasses, and lymphocyte compartments were examined. For further comparative analysis, all the subjects were divided into two groups, HIGM A-T and non-HIGM A-T. The clinical evaluation of the study group showed that recurrent respiratory tract infections due to viral and bacterial pathogens and a chronic obstructive airway disease along with impaired humoral immunity, in particular complete IgA deficiency, were noted in all the A-T patients, with both HIGM and non-HIGM phenotypes. The most important features with the discriminatory role between groups, were autoimmune disorders, observable four times more frequently in HIGM than in non-HIGM A-T. Two patients with the HIGM A-T phenotype were deceased due to liver failure and chronic Epstein-Barr virus (EBV) infection. It may therefore be assumed that the HIGM form of A-T is associated with more profound T cell dysfunction, defective immunoglobulin class switching, chronic EBV expansion, and poorer prognosis.
Identifiants
pubmed: 36340711
doi: 10.3389/fped.2022.972952
pmc: PMC9631935
doi:
Types de publication
Journal Article
Langues
eng
Pagination
972952Informations de copyright
© 2022 Szczawińska-Popłonyk, Tąpolska-Jóźwiak, Schwartzmann and Pietrucha.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Immunol. 2021 Jan;41(1):76-88
pubmed: 33052516
J Allergy Clin Immunol. 2013 May;131(5):1367-75.e9
pubmed: 23566627
Pediatr Res. 2016 Jun;79(6):889-94
pubmed: 26891003
Antioxidants (Basel). 2022 Mar 28;11(4):
pubmed: 35453338
Orphanet J Rare Dis. 2016 Nov 25;11(1):159
pubmed: 27884168
J Multidiscip Healthc. 2021 Jun 28;14:1637-1644
pubmed: 34234451
Immunol Invest. 2021 Feb;50(2-3):201-215
pubmed: 32116070
Neuropediatrics. 2012 Jun;43(3):119-29
pubmed: 22614068
J Pediatr. 2004 Apr;144(4):505-11
pubmed: 15069401
Neuropediatrics. 2003 Jun;34(3):165-7
pubmed: 12910443
J Immunoassay Immunochem. 2015;36(1):16-26
pubmed: 24568663
Front Immunol. 2018 Jun 25;9:1454
pubmed: 29988505
J Pediatr Gastroenterol Nutr. 2016 Apr;62(4):550-5
pubmed: 26594831
Parkinsonism Relat Disord. 2018 Jan;46:3-8
pubmed: 29249681
Eur Respir Rev. 2015 Dec;24(138):565-81
pubmed: 26621971
Nat Rev Mol Cell Biol. 2021 Dec;22(12):796-814
pubmed: 34429537
Immunol Res. 2021 Oct;69(5):436-444
pubmed: 34427868
Int J Mol Sci. 2021 Jul 13;22(14):
pubmed: 34299120
Expert Rev Clin Immunol. 2017 May;13(5):499-505
pubmed: 28162005
Eur Respir J. 2015 Dec;46(6):1557-60
pubmed: 26621885
Viruses. 2021 May 09;13(5):
pubmed: 34065066
J Clin Immunol. 2014 Jul;34(5):561-72
pubmed: 24789685
J Clin Immunol. 2021 Nov;41(8):1878-1892
pubmed: 34477998
Genes (Basel). 2021 Aug 31;12(9):
pubmed: 34573351
J Clin Immunol. 2022 May;42(4):783-797
pubmed: 35257272
Dev Dyn. 2018 Jan;247(1):33-46
pubmed: 28543935
Front Immunol. 2019 Sep 27;10:2322
pubmed: 31611883
PLoS One. 2022 Mar 15;17(3):e0264177
pubmed: 35290391
Clin Immunol. 2017 May;178:45-55
pubmed: 28126470
J Clin Immunol. 2020 Jan;40(1):66-81
pubmed: 32048120
BMC Pediatr. 2018 Jun 4;18(1):185
pubmed: 29866155
Front Immunol. 2018 Sep 18;9:2000
pubmed: 30279689
Pediatr Pulmonol. 2014 Jan;49(1):84-90
pubmed: 23401357
Exp Mol Pathol. 2020 Apr;113:104369
pubmed: 31917286
Clin Immunol. 2011 Jul;140(1):26-36
pubmed: 21459046
Front Pediatr. 2019 Nov 07;7:458
pubmed: 31788461
Ageing Res Rev. 2017 Jan;33:76-88
pubmed: 27181190
Redox Biol. 2020 May;32:101511
pubmed: 32244177
Postepy Dermatol Alergol. 2020 Oct;37(5):760-765
pubmed: 33240017
Growth Factors. 2014 Jun;32(3-4):123-9
pubmed: 25060036
Pediatr Pulmonol. 2014 Apr;49(4):389-99
pubmed: 23761391
J Immunol. 2012 Jul 1;189(1):261-8
pubmed: 22649200
Ital J Pediatr. 2010 Apr 11;36:29
pubmed: 20380744
Pediatr Pulmonol. 2010 Mar;45(3):230-5
pubmed: 20146367
Pediatr Pulmonol. 2005 Jun;39(6):537-43
pubmed: 15789441
DNA Repair (Amst). 2016 Mar;39:1-20
pubmed: 26777338
Front Immunol. 2019 Jan 04;9:3060
pubmed: 30662441
Viruses. 2017 Nov 16;9(11):
pubmed: 29144413
Front Pediatr. 2019 Oct 24;7:390
pubmed: 31709200
Dev Med Child Neurol. 2017 Jul;59(7):680-689
pubmed: 28318010
Front Pediatr. 2020 Jul 09;8:317
pubmed: 32733823
Front Pediatr. 2020 Nov 19;8:570330
pubmed: 33330270
Clin Exp Immunol. 2020 Oct;202(1):60-71
pubmed: 32691468